Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
  • Home
  • ICR Divisions
  • Genetics and Epidemiology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

FRMD6 has tumor suppressor functions in prostate cancer.

Thumbnail
View/Open
Accepted version (188.2Kb)
Date
2020-11-28
ICR Author
Kote-Jarai, Zsofia
Eeles, Rosalind
Author
Haldrup, J
Strand, SH
Cieza-Borrella, C
Jakobsson, ME
Riedel, M
Norgaard, M
Hedensted, S
Dagnaes-Hansen, F
Ulhoi, BP
Eeles, R
Borre, M
Olsen, JV
Olsen, JV
Thomsen, M
Kote-Jarai, Z
Sorensen, KD
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly hypermethylated and significantly downregulated gene in PC. Low FRMD6 expression was associated with postoperative biochemical recurrence in two large PC patient cohorts. In overexpression and CRISPR/Cas9 knockout experiments in PC cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice. Transcriptomic, proteomic, and phospho-proteomic profiling revealed enrichment of Hippo/YAP and c-MYC signaling upon FRMD6 knockout. Connectivity Map analysis and drug repurposing experiments identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells. Finally, we established orthotropic Frmd6 and Pten, or Pten only (control) knockout in the ROSA26 mouse prostate. After 12 weeks, Frmd6/Pten double knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferation, while Pten single-knockouts developed only regular PIN lesions and displayed lower proliferation. In conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate in PC.
URI
https://repository.icr.ac.uk/handle/internal/4294
DOI
https://doi.org/10.1038/s41388-020-01548-w
Collections
  • Genetics and Epidemiology
  • Radiotherapy and Imaging
Research team
Oncogenetics
Language
eng
Date accepted
2020-10-28
License start date
2020-11-28
Citation
Oncogene, 2020

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.